tirzepatide cardiovascular outcome trial outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Key milestones of tirzepatide in

GLP-1 medications, by contrast, have large randomized controlled trials proving 1518% average weight loss over one year

Why patients love Tirzepatide: Targets two hormones for enhanced weight loss potential May improve both appetite control and energy balance Early studies show significant results compared to other treatments Great alternative for those who experience side effects on Semaglutide Which Option Is Right for You

GLP1RA , (2018 2) (insulin glargine + lixisenatide)

However, if you have IBS and are considering or currently taking a GLP-1 medication, close monitoring and communication with your healthcare team is essential to optimise both conditions effectively

Keep your injections refrigerated unless we give you different instructions

Similarly, Zepbound (tirzepatide) received FDA approval for chronic weight management under similar criteria